A gene delivery system activatable by disease-associated matrix metalloproteinases

Human Gene Therapy

Volumn 8, Issue 6, 1997, Pages 729-738

  Peng, Kah Whye ^a   Morling, Frances J ^a   Cosset, François Loic ^b   Murphy, Gillian ^c   Russell, Stephen J ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b CNRS   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GLYCOPROTEIN; METALLOPROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; CELL DIVISION; CELL LINE; CLONING VECTOR; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; LEUKEMIA VIRUS; NONHUMAN; VIRUS PARTICLE;

EID: 0030994111     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.6-729     Document Type: Article

References (38)

1. AFZAL, S., LALANI, E.-N., FOULKES, W.D., BOYCE, B., TICKLE, S., CARDILLO, M.R., BAKER, T., PIGNATELLI, M., and STAMP, G.W.H. (1996). Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab. Invest. 74, 406-421.
2. COSSET, F.-L., TAKEUCHI, Y., BATTINI, J.-L., WEISS, R.A., and COLLINS, M.K.L. (1995a). High-liter packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69, 7430-7436.
3. COSSET, F.-L., MORLING, F.J., TAKEUCHI, Y., WEISS, R.A., COLLINS, M.K.L., and RUSSELL, S.J. (1995b). Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69, 6314-6322.
4. COUSSENS, L.M., and WERB, Z. (1996). Matrix metalloproteinases and the development of cancer. Curr. Biol. 3, 895-904.
5. EMMERT-BUCK, M.R., EMONARD, H.P., CORCORAN, M.L., KRUTZSCH, H.C., FOIDART, J.-M., and STETLER-STEVENSON, W.G. (1995). Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett. 364, 28-32.
6. GILLES, C., POLETTE, M., PIETTE, J., MUNAUT, C., THOMPSON, E.W., BIREMBAUT, P., and FOIDART, J.-M. (1996). High levels of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int. J. Cancer. 65, 209-213.
7. 2-macroglobulin. J. Biol. Chem. 266, 12329-12336.
8. HEPPNER, K.J., MATRISAN, L.M., JENSEN, R.A., and RODGERS, W.H. (1996). Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149, 273-282.
9. HODGSON, J. (1995). Remodeling MMPIs. Biotechnology 13, 554-557.
10. KARELINA, T.V., GOLDBERG, G.L., and EISEN, A.Z. (1995). Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors. J. Invest. Dermatol. 105, 411-417.
11. KASAHARA, N., DOZY, A.M., and KAN, Y.W. (1994). Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376.
12. LIOTTA, L.A., STEEG, P.S., and STETLER-STEVENSON, W.G. (1991). Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64, 327-336.
13. LOTTENBERG, R., CHRISTENSEN, U., JACKSON, C.M., and COLEMAN, P.L. (1981). Assay of coagulation proteases using peptide chromogenic and flurogenic substrates. Methods Enzymol. 80, 341-361.
14. MATANO, T., ODAWARA, T., IWAMOTO, A., and YOSHIKURA, H. (1995). Targeted infection of a retrovirus bearing a CD4-env chimera into human cells expressing human immunodeficiency virus type 1. J. Gen. Virol. 76, 3165-3169.
15. MODJTAHEDI, H., and DEAN, C. (1994). The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer. Int. J. Oncol. 4, 277-296.
16. MORLING, F.J., and RUSSELL, S.J. (1995). Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. Gene Ther. 2, 504-508.
17. NILSON, B.H.K., MORLING, F.J., COSSET, F.-L., and RUSSELL, S.J. ( 1996). Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 3, 280-286.
18. NORUMA, H., SATO, H., SEIKI, M., MAI, M., and OKADA, Y. (1995). Expression of membrane-type matrix metalloproteinase in human carcinomas. Can. Res. 55, 3263-3266.
19. NOMURA, H., FUJIMOTO, N., SEIKI, M., MAI, M., and OKADA, Y. (1996). Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer 69, 9-16.
20. NOURI, A.M.E., HUSSAIN, R.F., and OLIVER, R.T.D. (1995). Epidermal growth factor-induced protection of tumour cell susceptibility to cytolysis. J. Cancer. 31A, 963-969.
21. OKADA, A., BELLOCQ, J.-P., ROUYER, N., CHENARD, M.-P., RIO, M.-C., CHAMBON, P., and BASSET, P. (1995). Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA 92, 2730-2734.
22. PUENTE, X.S., PENDAS, A.M., LLANO, E., VELASCO, G., and LOPEZ-OTIN, C. (1996). Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 56, 944-949.
23. RAY, J.M., and STETLER-STEVENSON, W.G. (1994). The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur. Respir. J. 7, 2062-2072.
24. RUSSELL, S.J., HAWKINS, R.E., and WINTER, G. (1993). Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21, 1081-1085.
25. SAMBROOK, J., FRITSCH, E.F., and MANIATIS, T. (1989). Molecular Cloning: A Laboratory Manual. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
26. SATO, H., TAKAHISA, T., OKADA, Y., CAO, J., SHINAGAWA, A., YAMAMOTO, E., and SEIKI, M. (1994). A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61-65.
27. SOMIA, N.V., ZOPPE, M., and VERMA, I.M. (1995). Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA 92, 7570-7574.
28. STEPHENS, R.W., POLLANEN, J., TAPIOVAARA, H., LEUNG, K.-C., SIM, R-S., SALONEN, E.-M., RONNE, E., BEHRENDT, N., DANO, K., and VAHERI, A. (1989). Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surface-bound reactants. J. Cell Biol. 108, 1987-1995.
29. STETLER-STEVENSON, W.G., LIOTTA, L.A., and KLEINER, D.E., JR. (1993). Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 7, 1434-1441.
30. STRONGIN, A.Y., COLLIER, I., BANNIKOV, G., MARMER, B.L., GRANT, G.A., and GOLDBERG, G.I. (1995). Mechanisms of cell surface activation of 72-kDa type IV collagenase. J. Biol. Chem. 270, 5331-5338.
31. TAKEUCHI, Y., COSSET, F.-L., LACHMANN, P.J., OKADA, H., WEISS, R.A., and COLLINS, M.K.L. (1994). Type C retrovirus inactivation by human complement is determined by both the viral genome and producer cell. J. Virol. 68, 8001-8007.
32. TAKINO, T., SATO, H., SHINAGAWA, A., and SEIKI, M. (1995). Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. J. Biol. Chem. 270, 23013-23020.
33. VALSESIA-WITTMANN, S., DRYNDA, A., DELEAGE, G., AUMAILLEY, M., HEARD, J.-M., DANOS, O., VERDIER, G., and COSSET, F.-L. (1994). Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68, 4609-4619.
34. WILL, H., and HINZMANN, B. (1995). cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur. J. Biochem. 231, 602-608.
35. WILL, H., ATKINSON, S.J., BUTLER, G.S., SMITH, B., and MURPHY, G. (1996). The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autocatalytic activation. J. Biol. Chem. 271, 17119-17123.
36. WOESSNER, J.F., JR. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5, 2145-2154.
37. YE, Q.-Z., JOHNSON, L.L., YU, A.E., and HOPE, D. (1995). Reconstructed 19kDa catalytic domain of gelatinase A is an active proteinase. Biochemistry 34, 4702-4708.
38. YOUNG, T.N., PIZZO, S., and STACK, S. (1995). A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J. Biol. Chem. 270, 999-1002.